glp-1 receptor agonist diarrhea management Treating bile acid with agonists GLP1 and GIP Receptor Agonists:

While cardiovascular outcome data for retatrutide is still accumulating, the prudent approach for anyone with active cardiovascular disease is to remain on compounds with established cardiovascular safety profiles

How may GIP Enhance the therapeutic efficacy of GLP-1

One 2026 narrative review concluded that GLP-1 receptor agonist therapy is associated with meaningful nutritional deficiencies and that individualized nutritional assessment and lab evaluation may be appropriate, especially in people at higher risk of malnutrition

In the brain, GLP-1s reduce appetite and cravings (the fundamental mechanism of addictive disease)

Reassuringly, only a very small percentage of people with T2D experienced hypoglycaemia in the phase 2 trial which included people on lifestyle interventions or metformin

In summary, tirzepatide modulates metabolic and inflammatory pathways that may enhance airway stability in obesity-related OSAS (Figure 2)